Related Experiment Video
Updated: May 6, 2026

Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts
Published on: September 1, 2018
Immunotherapy for high-grade glioma: how to go beyond Phase I/II clinical trials
1Laboratory of Pediatric Immunology, Pediatric Neuro-Oncology, University of Leuven, Herestraat 49, 3000 Leuven, Belgium. stefaan.vangool@uzleuven.be.
Abstract:
Evaluation of: Lasky JL 3rd, Panosyan EH, Plant A et al. Autologous tumor lysate-pulsed dendritic cell immunotherapy for pediatric patients with newly diagnosed or recurrent high-grade gliomas. Anticancer Res. 33, 2047-2056 (2013). Immunotherapy for children and adults with high-grade glioma (HGG) is an emerging innovative treatment approach, which aims at stimulating the body's own immune system against HGG by using autologous dendritic cells pulsed with autologous tumor lysate as a therapeutic vaccine. This is the third report on immunotherapy for HGG in children, bringing additional knowledge and experience to the scientific community. However, at the same time, this and other manuscripts urge for the next step in treatment development.
Related Concept Videos
Tumor Immunotherapy
Clinical Trials: Overview
Clinical Trials
There are four phases in a clinical trial. A phase one...

